DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis

被引:0
作者
Li-Li Dong [1 ,2 ,3 ]
Ru Tang [3 ,4 ]
Yu-Jia Zhai [3 ]
Tejsu Malla [3 ]
Kai Hu [1 ,5 ]
机构
[1] Department of Ophthalmology, Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Nanjing University
[2] Department of Ophthalmology, Jiangsu Taizhou People’s Hospital
[3] Medical School of Southeast University
[4] Department of Ophthalmology, the People’s Hospital of Danyang
[5] Nanjing Ning Yi Eye Center
关键词
herpes simplex virus 1; keratitis; gC-based DNA vaccine; nanocarrier; immune response;
D O I
暂无
中图分类号
R772.21 [角膜炎、角膜溃疡];
学科分类号
100212 ;
摘要
AIM: To investigate whether DNA vaccine encoding herpes simplex virus 1(HSV-1) glycoprotein C(g C) and glycoprotein D(g D) will achieve better protective effect against herpes simplex keratitis(HSK) than DNA vaccine encoding gD alone. METHODS: DNA vaccine expressing gD or gC combined g D(g D.g C) were constructed and carried by chitosan nanoparticle. The expression of fusion protein gD and gC were detected in DNA/nanoparticle transfected 293 T cells by Western-blot. For immunization, mice were inoculated with DNA/nanoparticle for 3 times with 2 wk interval, and two weeks after the final immunization, the specific immune responses and clinical degrees of primary HSK were evaluated. RESULTS: Fusion protein g D.g C could be expressed successfully in cultured 293 T cells. And, p RSC-g C.g DIL21 DNA/chitosan nanoparticle could effectively elicit strongest humoral and cellular immune response in primary HSK mice evidenced by higher levels of specific neutralizing antibody and s Ig A production, enhanced cytotoxicities of splenocytes and nature killer cells(NK),when compared with those of gD alone or mocked vaccine immunized mice. As a result, gC-based vaccine immunized mice showed least HSK disease. CONCLUSION: gC-based DNA vaccine could effectively prevent the progress of primary HSK, suggesting that this DNA vaccine could be a promising vaccine for HSK treatment in the future.
引用
收藏
页码:1633 / 1639
页数:7
相关论文
共 12 条
[1]   Characterization of pDNA-TMC Nanoparticle Interaction and Stability [J].
Poecheim, Johanna ;
Patrulea, Viorica ;
Reichert, Christian ;
Borchard, Gerrit .
CURRENT DRUG DELIVERY, 2016, 13 (03) :301-308
[2]  
Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials[J] . Daniel Elieh-Ali-Komi,Michael R Hamblin..International Journal of Advanced Research (IJAR) . 2016 (3)
[3]  
Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity[J] . D. Bento,H.F. Staats,T. Gon?alves,O. Borges.European Journal of Pharmaceutics and Biopharmace . 2015
[4]   Using Plasmids as DNA Vaccines for Infectious Diseases [J].
Tregoning, John S. ;
Kinnear, Ekaterina .
MICROBIOLOGY SPECTRUM, 2014, 2 (06)
[5]  
Herpes keratitis[J] . A.M. Rowe,A.J. St. Leger,S. Jeon,D.K. Dhaliwal,J.E. Knickelbein,R.L. Hendricks.Progress in Retinal and Eye Research . 2013
[6]  
Herpes Simplex Epithelial and Stromal Keratitis: An Epidemiologic Update[J] . Asim V. Farooq,Deepak Shukla.Survey of Ophthalmology . 2012 (5)
[7]   Immunization with DNA Vaccine Expressing Herpes Simplex Virus Type 1 gD and IL-21 Protects against Mouse Herpes Keratitis [J].
Hu, Kai ;
He, Xiangfeng ;
Yu, Fangliu ;
Yuan, Xianwen ;
Hu, Weihua ;
Liu, Chunsheng ;
Zhao, Fengshu ;
Dou, Jun .
IMMUNOLOGICAL INVESTIGATIONS, 2011, 40 (03) :265-278
[8]   Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine [J].
Awasthi, Sita ;
Lubinski, John M. ;
Friedman, Harvey M. .
VACCINE, 2009, 27 (49) :6845-6853
[9]   A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination [J].
Arefian, E. ;
Bamdad, T. ;
Soleimanjahi, H. ;
Akhoond, M. R. ;
Parsania, M. ;
Ghaemi, A. .
MOLECULAR BIOLOGY, 2009, 43 (03) :388-393
[10]   Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains [J].
Chang, YJ ;
Jiang, M ;
Lubinski, JM ;
King, RD ;
Friedman, HM .
VACCINE, 2005, 23 (38) :4658-4665